Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.

about

Inhibitory effect of single and repeated doses of nilotinib on the pharmacokinetics of CYP3A substrate midazolam.

Item

http://www.wikidata.org/entity/Q47787457

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@en

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@nl

type

Item

label

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@en

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@nl

prefLabel

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@en

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@nl

P1476

Inhibitory effect of single an ...... of CYP3A substrate midazolam.

@en

P2093

Cheng Zheng

http://www.w3.org/2001/XMLSchema#string

Hefei Zhang

http://www.w3.org/2001/XMLSchema#string

Jennifer Sheng

http://www.w3.org/2001/XMLSchema#string

Jin H Ko

http://www.w3.org/2001/XMLSchema#string

Petra Priess

http://www.w3.org/2001/XMLSchema#string

Steven Novick

http://www.w3.org/2001/XMLSchema#string

Wei Zhou

http://www.w3.org/2001/XMLSchema#string

Wen Lin

http://www.w3.org/2001/XMLSchema#string

P2860

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States

Nilotinib: a second-generation tyrosine kinase inhibitor for chronic myeloid leukemia

Extended kinase profile and properties of the protein kinase inhibitor nilotinib

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.

A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.

In vitro and in vivo drug interactions involving human CYP3A.

Nilotinib: a new tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase.

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study.

P304

401-408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.434

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25418605

http://www.w3.org/2001/XMLSchema#string